PD 325901

Drug Profile

PD 325901

Alternative Names: PD-0325901; PD-325901

Latest Information Update: 05 Jul 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Pfizer; University of Alabama at Birmingham; University of Oxford
  • Class Aniline compounds; Antineoplastics; Benzamides; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neurofibromatoses
  • Phase I Colorectal cancer
  • Discontinued Breast cancer; Cancer; Malignant melanoma; Non-small cell lung cancer

Most Recent Events

  • 26 Jun 2016 University of Oxford completes a phase-I trial in Colorectal cancer (Combination therapy) in United Kingdom, Belgium (PO) (NCT02510001)
  • 15 Mar 2016 Biomarkers information updated
  • 28 Jul 2015 Discontinued - Phase-I for Cancer (Combination therapy, Late-stage disease) in Spain, Italy, Canada, USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top